Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia

被引:1
作者
Griffen, Ti'ara L. [1 ]
Hoff, Fieke W. [2 ]
Qiu, Yihua [3 ]
Burger, Jan [3 ]
Wierda, William [3 ]
Kornblau, Steven M. [3 ]
机构
[1] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA
[2] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
CLL; proteomics DDR; 17P DELETION; REPAIR; MUTATIONS; ENDONUCLEASE; RESISTANCE; ERCC1-XPF; CELLS;
D O I
10.3390/ijms24065481
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteomic DNA Damage Repair (DDR) expression patterns in Chronic Lymphocytic Leukemia were characterized by quantifying and clustering 24 total and phosphorylated DDR proteins. Overall, three protein expression patterns (C1-C3) were identified and were associated as an independent predictor of distinct patient overall survival outcomes. Patients within clusters C1 and C2 had poorer survival outcomes and responses to fludarabine, cyclophosphamide, and rituxan chemotherapy compared to patients within cluster C3. However, DDR protein expression patterns were not prognostic in more modern therapies with BCL2 inhibitors or a BTK/PI3K inhibitor. Individually, nine of the DDR proteins were prognostic for predicting overall survival and/or time to first treatment. When looking for other proteins that may be associated with or influenced by DDR expression patterns, our differential expression analysis found that cell cycle and adhesion proteins were lower in clusters compared to normal CD19 controls. In addition, cluster C3 had a lower expression of MAPK proteins compared to the poor prognostic patient clusters thus implying a potential regulatory connection between adhesion, cell cycle, MAPK, and DDR signaling in CLL. Thus, assessing the proteomic expression of DNA damage proteins in CLL provided novel insights for deciphering influences on patient outcomes and expanded our understanding of the potential complexities and effects of DDR cell signaling.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] The role of TACI expression in chronic lymphocytic leukemia
    Bojarska-Junak, Agnieszka
    Hus, Iwona
    Sieklucka, Malgorzata
    Surdacka, Agata
    Kusz, Maria Luiza
    Wasik-Szczepanek, Ewa
    Dmoszynska, Anna
    Rolinski, Jacek
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 36 (01) : 46 - 50
  • [22] Increased Expression of Autophagy Protein LC3 in Two Patients With Progressing Chronic Lymphocytic Leukemia
    Arroyo, Daniela S.
    Rodriguez, Cecilia M.
    Bussi, Claudio
    Manzone-Rodriguez, Clarisa
    Sastre, Dario
    Heller, Viviana
    Stanganelli, Carmen
    Slavutsky, Irma
    Iribarren, Pablo
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [23] DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
    Tsagiopoulou, Maria
    Papakonstantinou, Nikos
    Moysiadis, Theodoros
    Mansouri, Larry
    Ljungstrom, Viktor
    Duran-Ferrer, Marti
    Malousi, Andigoni
    Queiros, Ana C.
    Plevova, Karla
    Bhoi, Sujata
    Kollia, Panagoula
    Oscier, David
    Anagnostopoulos, Achilles
    Trentin, Livio
    Ritgen, Matthias
    Pospisilova, Sarka
    Stavroyianni, Niki
    Ghia, Paolo
    Martin-Subero, Jose I.
    Pott, Christiane
    Rosenquist, Richard
    Stamatopoulos, Kostas
    CLINICAL EPIGENETICS, 2019, 11 (01)
  • [24] Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
    Serpa, Mariana
    Bendit, Israel
    Seguro, Fernanda
    Xavier, Flavia
    Cavalcante, Marcela
    Steinbaum, Daniel
    Nardinelli, Luciana
    Aldred, Vera Lucia
    de Paula, Henrique Moura
    Dorlhiac-Llacer, Pedro Enrique
    ACTA HAEMATOLOGICA, 2010, 124 (02) : 105 - 109
  • [25] Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?
    Best, O. Giles
    Tam, Constantine
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2098 - 2099
  • [26] Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia
    Kazi, Julhash U.
    Kabir, Nuzhat N.
    Ronnstrand, Lars
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [27] BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia
    Chong, Stephen Jun Fei
    Lu, Junyan
    Valentin, Rebecca
    Lehmberg, Timothy Z.
    Eu, Jie Qing
    Wang, Jing
    Zhu, Fen
    Kong, Li Ren
    Fernandes, Stacey M.
    Zhang, Jeremy
    Herbaux, Charles
    Goh, Boon Cher
    Brown, Jennifer R.
    Niemann, Carsten U.
    Huber, Wolfgang
    Zenz, Thorsten
    Davids, Matthew S.
    MOLECULAR CANCER, 2025, 24 (01)
  • [28] Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico
    Ortiz-Ortiz, Karen J. J.
    Torres-Cintron, Carlos R. R.
    Ramos, Tonatiuh Suarez
    Castaneda-Avila, Maira A. A.
    Cotto Santana, Luis A. A.
    Tortolero-Luna, Guillermo
    CANCER MEDICINE, 2023, 12 (06): : 6889 - 6901
  • [29] Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia
    Del Giudice, Ilaria
    Della Starza, Irene
    De Falco, Filomena
    Gaidano, Gianluca
    Sportoletti, Paolo
    CANCERS, 2024, 16 (11)
  • [30] AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations
    Leuenberger, Mona
    Frigerio, Simona
    Wild, Peter J.
    Noetzli, Franziska
    Korol, Dimitri
    Zimmermann, Dieter R.
    Gengler, Carole
    Probst-Hensch, Nicole M.
    Moch, Holger
    Tinguely, Marianne
    MODERN PATHOLOGY, 2010, 23 (02) : 177 - 186